Gutpraz LSV Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, indicated for the treatment of various gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of Levosulpiride and Rabeprazole in Gutpraz LSV Capsule offers comprehensive management of functional dyspepsia and acid-peptic disorders by improving gastric motility and reducing gastric acidity. This combination is particularly beneficial in patients presenting with symptoms of delayed gastric emptying accompanied by acid reflux. Gutpraz LSV Capsule should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with renal or hepatic impairment. Adverse effects may include headache, dizziness, and gastrointestinal disturbances. Regular monitoring is advised to ensure therapeutic efficacy and safety.